Relay Therapeutics (RLAY) Soars 5.4%: Is Further Upside Left in the Stock?

Group 1 - Relay Therapeutics, Inc. (RLAY) shares increased by 5.4% to $10.69, with a notable trading volume, reflecting a 17.2% gain over the past four weeks [1][2] - The rise in share price is attributed to investor optimism regarding Relay Therapeutics' clinical pipeline, particularly the development of zovegalisib (RLY-2608) for advanced breast cancer [2] - The company is conducting a phase III study (ReDiscover-2) for zovegalisib in combination with AstraZeneca's Faslodex, showing potential improvements in tolerability and progression-free survival [2] Group 2 - Relay Therapeutics is expected to report a quarterly loss of $0.36 per share, a year-over-year increase of 21.7%, with revenues projected at $15.35 million, up 99.9% from the previous year [3] - The consensus EPS estimate for Relay Therapeutics has been revised 15.7% higher in the last 30 days, indicating a positive trend that may lead to price appreciation [4] - Relay Therapeutics holds a Zacks Rank of 3 (Hold), indicating a neutral outlook compared to other stocks in the Zacks Medical - Drugs industry [4]